Toyama's flu drug progresses in US as peramivir filed for paediatric use in Japan
This article was originally published in Scrip
Executive Summary
Toyama Chemical has begun a Phase II clinical trial in the US with its novel oral antiviral agent favipiravir (T-705), becoming the latest Japanese firm to take forward a new treatment option for flu infections.